This editorial refers to 'Control of p21 Cip by BRCA1-associated protein is critical for cardiomyocyte cell cycle progression and survival ', by C. Volland et al., 
One of the greatest challenges in heart regeneration is to replace lost myocardium by generating new cardiomyocytes. Recent findings showing that there are no myogenic stem cells in the mammalian heart, 1, 2 together with the observation that a small percentage of adult human cardiomyocytes retains the capacity to renew, 3 have shifted the focus to augmenting proliferation of endogenous cardiomyocytes. This spiked a huge interest in understanding cardiomyocyte cell cycle regulation, resulting in several studies showing successful induction of proliferation in adult cardiomyocytes. [4] [5] [6] During developmental and adult stages, mammalian cardiomyocytes go through several stages of growth and decline. Pre-natal growth is characterized by cardiomyocyte proliferation, followed by postnatal hypertrophic growth marked by binucleation and polyploidization, whereas aged hearts suffer from cardiomyocyte apoptosis. All these stages require a specific regulation of the cell cycle and how cardiomyocytes manage to fine-tune this remains poorly understood.
In the present report, Volland et al. 7 describe BRCA-1-associated protein (BRAP) as a regulator of the cardiomyocyte cell cycle ( Figure 1 ). Previously, BRAP has been shown to act as a key regulator for Ras-to-Erk signalling. 8 Furthermore, a loss of BRAP led to a delay in S phase and stalled G2 phase in neural progenitor cells by controlling p27 Kip1 degradation through targeting Skp2. 9 Volland et al., BRAP exerted specific effects on cardiomyocytes depending on the stage of cardiac development in mice. BRAP expression levels dropped coinciding with the loss of the proliferative capacity of cardiomyocytes during the neonatal period and declined even further in adults. 7 To test the hypothesis that BRAP plays a functional role in regulating the cardiomyocyte cell cycle during development, the authors generated several genetic loss-and gain-of-function mouse models. An unconditional knock-out of Brap led to embryonic lethality due to developmental retardation in several organ systems. Importantly, next to signs of cardiac congestion, the embryonic heart also showed thinning of trabecular and compact layers of the ventricular myocardium. This suggests that this congestion is a consequence of a lack of contractile tissue. This finding was supported by showing that directed ablation of BRAP in early embryonic cardiomyocytes using Nkx2.5-Cre and Mlc2V-Cre recombinase lines was sufficient to induce embryonic lethality. In contrast, aMHC-Cre/Brap fl/fl mice survived until the first postnatal days, allowing the authors to explore the effect of BRAP expression on cardiomyocyte proliferation in the perinatal period, when cardiomyocytes withdraw gradually from the cell cycle and undergo polyploidization. 10 A specific knock-out of Brap caused a reduction of cell cycle activity with a decrease in cardiomyocyte proliferation and binucleation at post-natal Day 4. Next, the authors investigated the effect of Brap knock-out in adult hearts, which have a limited renewal capacity. Brap was specifically deleted in adult cardiomyocytes using the tamoxifen-inducible aMHC-MerCreMer mouse crossed to the Brap fl/fl mouse. In contrast to neonatal mice, the authors found multiple morphological changes comprising a cardiomyopathy phenotype, including the deterioration of cardiac function with increased dilatation. This was accompanied by cardiomyocyte hypertrophy, fibrosis, and increased apoptosis.
To understand how BRAP affects cardiomyocyte cell cycle and survival, a transcriptional analysis of Brap knock-out mice was performed. This revealed a decrease in cell cycle promoting genes such as Cyclin D1 and Cdk2, as well as a drastic increase of the cyclindependent kinase inhibitor Cdkn1a gene (p21 Cip1 ), which is an important negative regulator of the cell cycle and is required for G1/S transition. As BRAP is a negative regulator of nuclear import, 11 its deletion not only increases p21 Cip1 expression but also leads to an accumulation of p21 Cip1 in the nucleus. p21 Cip1 has been described as a regulator for replicative senescence, apoptosis, and DNA damage response depending on its cellular localization. 12 Cytoplasmic p21 Cip1 protects against apoptosis, 13 whereas nuclear p21 Cip1 inhibits cell division and growth. 12 Accordingly, the reported increase in nuclear p21 Cip1 in Brap knock-out mice might have altered the nuclear/cytoplasmic ratio of p21 Cip1 , blocking its anti-apoptotic cytoplasmic effect. Whether the reported cardiomyopathy phenotype is only elicited by the up-regulation of p21 Cip1 , causing an increase in apoptosis, or if the knock-down of Brap acts through different pathways needs to be investigated. 14 Moreover, the authors addressed whether Brap overexpression could stimulate cardiomyocyte proliferation. Although cell cycle activity was augmented in neonatal cardiomyocytes, no increase in mitosis was observed, suggesting that overexpression of Brap is essential to promote cell cycle entry, but might not be sufficient to stimulate the progression to mitosis and cytokinesis in neonates. Whether continued overexpression of Brap in adult hearts would lead to similar effects or even induced cardiomyopathy has not been addressed. In other studies, down-regulation of pocket proteins, including p21 Cip1 , was shown to lead to hypertrophy and eventually to dilated cardiomyopathy. 15 Moreover, it remains to be determined whether BRAP regulation could have a positive effect on cardiac injuries, such as myocardial infarction and induced pressure overload.
The work by Volland et al. has generated insights into the role of BRAP on cardiac regeneration. However, future studies will need to decipher its complete role as a potential switch between cell cycle activity in foetal and neonatal cardiomyocyte and survival of adult cardiomyocytes.
